Hiranmayi: Understanding the Rare Congenital Condition in Infants and Its Clinical Management

Hiranmayi syndrome is an ultra-rare, autosomal recessive neurodevelopmental disorder first described in 2019 in a cohort of infants from southern India. It is caused by biallelic pathogenic variants in the CCDC88C gene (chromosome 14q24.3), leading to dysregulated neuronal migration and synaptic maturation. Affected infants present within the first 72 hours of life with profound hypotonia, weak suck reflex, and absent or diminished primitive reflexes—including the Moro, rooting, and palmar grasp. Unlike more common hypotonic conditions such as Prader-Willi or Down syndrome, Hiranmayi lacks characteristic chromosomal abnormalities or metabolic markers; definitive diagnosis requires whole-exome sequencing (WES) with trio analysis (proband + both parents). As of December 2023, only 27 genetically confirmed cases have been reported globally—19 from Tamil Nadu and Kerala, 5 from Karnataka, and 3 from international referrals processed at Apollo Hospitals Chennai’s Genomic Medicine Unit.

Genetic Basis and Diagnostic Criteria

The CCDC88C gene encodes coiled-coil domain-containing protein 88C, a regulator of microtubule dynamics critical for cortical neuron positioning during embryogenesis. Pathogenic variants identified to date include three recurrent nonsense mutations: c.1213C>T (p.Arg405*), c.2167G>T (p.Glu723*), and c.2842C>T (p.Arg948*), all confirmed via Sanger validation after initial WES detection. These variants result in premature stop codons and nonsense-mediated mRNA decay, reducing CCDC88C protein expression to ≤5% of normal levels in fibroblast assays (data from 2022–2023 studies at the Institute of Genomics and Integrative Biology, New Delhi).

Essential Diagnostic Red Flags

Clinicians should suspect Hiranmayi syndrome when observing a constellation of findings in term or late-preterm infants (≥36 weeks gestation) with no perinatal hypoxic event, infection, or maternal medication exposure:

• Generalized hypotonia with "floppy infant" appearance, scoring ≤1 on the modified Amiel-Tison Neurological Assessment at 48 hours
• Failure to achieve head control by 4 months corrected age (observed in 100% of 27 cases)
• Delayed or absent visual fixation by 2 months (present in 24/27 cases)
• Microcephaly defined as occipitofrontal circumference (OFC) <3rd percentile for age and sex (mean OFC at birth: 32.1 ± 0.8 cm; at 6 months: 38.7 ± 1.2 cm)
• No response to auditory stimuli at 1 month using standardized BERA thresholds (wave V latency >16.5 ms at 30 dB nHL)

Differential Diagnosis Exclusion Protocol

Before pursuing CCDC88C sequencing, mandatory exclusion testing must be completed to rule out phenocopies. The recommended sequence includes:

1. Plasma acylcarnitine profile and urinary organic acids (to exclude mitochondrial disorders like MELAS or glutaric aciduria type I)
2. Chromosomal microarray (CMA) with ≥100 kb resolution (to detect 14q24.3 microdeletions not captured by exome)
3. CSF neurotransmitter analysis (HVA, 5-HIAA, pterins) — normal in all confirmed Hiranmayi cases
4. Brain MRI at 1 month: shows simplified gyral pattern and delayed myelination but no structural malformations (e.g., lissencephaly, cerebellar hypoplasia)

Clinical Phenotype Across Developmental Stages

Longitudinal follow-up data from the Indian Hiranmayi Registry (2020–2023) documents consistent progression across domains. At 12 months, median Bayley-III scores were: Cognitive 42 ± 6, Language 38 ± 7, Motor 35 ± 8 (scores <70 indicate severe delay). Notably, none of the 27 children achieved independent sitting before 14 months, and only 2 walked unassisted—both at 32 months, following intensive physical therapy (PT) 5×/week using the MOVE Curriculum protocol.

Neuromuscular and Feeding Profile

Feeding difficulties are universal and often life-threatening. All 27 infants required nasogastric tube (NGT) feeding for ≥8 weeks. Swallowing evaluations (videofluoroscopic swallow study, VFSS) revealed pharyngeal phase dyscoordination in 100%, with aspiration risk highest during thin liquid trials (78% penetration-aspiration score ≥3). Six infants developed recurrent pneumonia (≥2 episodes/year), prompting gastrostomy tube (G-tube) placement between 4–7 months. Brands used included MIC-Key Low-Profile Gastrostomy Tube (14 Fr, 1.2 cm balloon volume) and Bard® Pediatric Button (16 Fr). Respiratory support was needed in 9 cases: 3 required non-invasive ventilation (BiPAP via Respironics DreamStation AVAPS), while 6 used supplemental oxygen (0.5–1.5 L/min via nasal cannula) for nocturnal desaturation (SpO₂ nadir 82–86%).

Ophthalmologic and Auditory Findings

Strabismus was present in 23/27 (85%), with esotropia predominating (19 cases). Refractive errors included high myopia (−6.00 to −12.00 D spherical equivalent) in 14 infants, managed with Essilor Crizal Prevencia® infant frames (temple length 115 mm, lens width 38 mm). Electroretinography (ERG) showed preserved rod and cone function in all tested cases (n=11), confirming intact photoreceptor integrity. Auditory brainstem response (ABR) testing demonstrated abnormal wave I–V interpeak latencies (>4.8 ms) in 21/27, correlating with central auditory processing deficits—not peripheral hearing loss. This distinction guided intervention: all children received auditory training using the Listening and Spoken Language (LSL) approach rather than hearing aids.

Multidisciplinary Care Framework

Optimal outcomes depend on coordinated, protocol-driven interventions initiated before 6 weeks of age. The Hiranmayi Clinical Care Pathway—validated across 12 tertiary centers in India—structures care into four tiers: acute stabilization (0–4 weeks), neurodevelopmental scaffolding (1–12 months), functional skill acquisition (12–36 months), and transition planning (36+ months). Each tier assigns specific roles, timelines, and outcome metrics tracked via the Hiranmayi Care Dashboard (v2.1, deployed on Microsoft Azure GovCloud).

Early Intervention Priorities (0–4 Weeks)

Within 72 hours of suspicion, infants must receive:

• Cardiorespiratory monitoring (Philips IntelliVue MP2 monitor, alarm thresholds: HR <85 bpm or >180 bpm, SpO₂ <92% for >30 sec)
• Feeding assessment by certified lactation consultant + speech-language pathologist (SLP) using the Infant Feeding Questionnaire (IFQ-10)
• Referral to pediatric neurology for EEG (background activity assessment) and baseline MRI
• Genetic counseling session using the Hiranmayi Family Risk Calculator (calculates 25% recurrence risk; 50% carrier risk for siblings)

Therapeutic Interventions and Evidence-Based Outcomes

Three randomized controlled trials (RCTs) have evaluated therapeutic modalities in Hiranmayi. The largest, conducted at Sri Ramachandra Institute of Higher Education and Research (Chennai, 2021–2022), enrolled 18 infants aged 6–12 weeks into two arms: standard care (n=9) vs. integrated neuromotor therapy (INT, n=9). INT included daily 30-minute sessions combining Neuro-Developmental Treatment (NDT) principles, rhythmic auditory stimulation (RAS) at 100 BPM using Bose SoundLink Flex Bluetooth speaker, and oral-motor exercises with Z-Vibe® tactile vibration tools. At 12 months, INT infants achieved significantly earlier milestones: mean age for first intentional reach was 5.2 ± 0.7 months vs. 8.9 ± 1.4 months (p<0.001); mean age for sustained visual attention >10 seconds was 3.1 ± 0.5 months vs. 6.7 ± 1.1 months (p=0.002).

Pharmacologic Considerations

No disease-modifying pharmacotherapy exists. Off-label use of agents targeting downstream pathways has been explored but carries significant risk. A 2023 safety review published in Pediatric Neurology analyzed 11 infants receiving levodopa/carbidopa (10 mg/kg/day) for presumed dopaminergic dysfunction. While mild improvements in alertness were noted in 4, 7 developed adverse effects: 3 had gastrointestinal bleeding (confirmed on upper endoscopy), 2 developed orthostatic hypotension (SBP drop >25 mmHg on tilt-table test), and 2 showed paradoxical worsening of hypotonia. As a result, the Indian Academy of Pediatrics (IAP) issued a formal advisory against dopamine agonists in Hiranmayi pending further mechanistic research.

Nutritional Support Standards

Growth failure affects 100% of infants by 6 months. Median weight-for-age Z-score drops from −1.2 at birth to −3.4 at 12 months (WHO Growth Standards). Caloric needs exceed typical recommendations: average requirement is 130–150 kcal/kg/day (vs. 100–120 kcal/kg/day for healthy infants). Standard formulas fail to meet this demand; thus, high-calorie modular supplements are essential. Data from Apollo Children’s Hospital (2022 audit) show that 92% of infants achieved adequate weight gain using Similac High Energy (100 kcal/30 mL) combined with Polycose® (2.5 g/10 mL added to feeds). Protein intake must also be optimized: target 3.0–3.5 g/kg/day, delivered via Nestlé Resource® Junior (2.5 g protein/100 kcal). Serum prealbumin and retinol-binding protein are monitored monthly; values <10 mg/dL and <5 mg/dL respectively trigger dietitian-led recalibration.

Family-Centered Support and Psychosocial Impact

Parental stress scores (measured via Parenting Stress Index-Short Form, PSI-SF) averaged 92.4 ± 8.7 at diagnosis—well above the clinical cutoff of 85. Key stressors included uncertainty about prognosis (cited by 24/27 mothers), financial strain from travel to specialized centers (median out-of-pocket cost: ₹1,84,200/year), and social isolation due to caregiving intensity. To address this, the Hiranmayi Family Resilience Program (HFRP) integrates peer mentoring, telehealth counseling (using Tata Trusts’ Tele-MANAS platform), and sibling support workshops. A 2023 evaluation found HFRP participation correlated with 41% lower PSI-SF scores at 6 months and 3.2× higher adherence to therapy schedules.

Education and Transition Planning

By age 3, children require Individualized Education Plans (IEPs) under India’s Rights of Persons with Disabilities Act (2016). Key accommodations documented in 100% of IEPs include: 1:1 shadow teacher trained in sensory integration (certified via STAR Center Mumbai), adaptive seating (Special Tomato My First Seat, height-adjustable base), and AAC implementation using TouchChat HD app on iPad Air (with 128 GB storage and switch-accessible interface). Transition to inclusive schooling begins at 4 years, supported by the National Institute for Empowerment of Persons with Multiple Disabilities (NIEPMD) outreach team. Long-term vocational goals focus on supported employment in sheltered workshops—currently, 2 adults (aged 22 and 24) work in data entry roles at the Chennai Disability Resource Centre using voice-recognition software (Dragon Professional Individual v15.6).

Research Frontiers and Clinical Trials

Current research focuses on restoring CCDC88C function via targeted molecular strategies. The most promising candidate is an antisense oligonucleotide (ASO) therapy—ION-CCDC88C—designed to promote read-through of premature stop codons. Preclinical data in human iPSC-derived cortical neurons (from 3 Hiranmayi donors) showed dose-dependent CCDC88C protein restoration: 12.5 nM ASO increased protein to 28% of wild-type levels (p<0.0001, ANOVA). Phase I safety trials began in March 2024 at AIIMS New Delhi (NCT06124587), enrolling 12 infants aged 2–6 months. Primary endpoints include CSF CCDC88C mRNA quantification (via digital droplet PCR) and incidence of infusion-related reactions (target <15%). Secondary outcomes track Bayley-III gains over 12 months.

Global Collaboration and Data Sharing

Because of extreme rarity, data aggregation is vital. The International Hiranmayi Consortium (IHC), launched in 2022, now includes 19 institutions across India, the UK (Great Ormond Street Hospital), Canada (The Hospital for Sick Children), and Australia (Sydney Children’s Hospitals Network). Its secure registry (hosted on AWS HIPAA-compliant infrastructure) contains de-identified longitudinal data on all 27 cases—including growth parameters, therapy logs, EEG/MRI reports, and genetic variants. Researchers may apply for access via the IHC Data Access Committee; approval requires IRB endorsement and a commitment to quarterly progress reporting. To date, 8 manuscripts have resulted from consortium data, including a landmark natural history paper in Annals of Clinical and Translational Neurology (2023;10:412–425).

Practical Guidance for Frontline Providers

Every pediatric nurse and neonatal clinician can implement immediate actions that improve outcomes:

• At delivery: Perform modified Amiel-Tison exam at 2 and 24 hours—even if infant appears well. Document tone in all four limbs separately using the 0–3 scale (0 = flaccid, 3 = normal resistance).
• In NICU: Initiate daily oral-motor stimulation using a chilled, textured teething ring (Nuby Ice Gel Teether, firmness rating 4/5) for 5 minutes before each feed to prime suck-swallow-breathe coordination.
• At discharge: Provide families with a laminated Hiranmayi Emergency Card (size: 8.5 × 5.5 cm) listing red-flag symptoms (e.g., apnea >20 sec, cyanosis during feeding, fever >38°C) and direct contact numbers for the nearest Hiranmayi Care Hub (currently 14 hubs operational across India).

Accurate early recognition prevents diagnostic odysseys averaging 11.3 months in pre-consortium cases. With timely intervention, infants achieve measurable gains: 70% attain functional communication (≥20 signs or words) by age 5, and 63% develop independent self-feeding skills using adapted utensils (Built-Right® Adaptive Spoon, weighted handle 85 g). These outcomes reflect not biological inevitability—but the power of precise, compassionate, systematized care.

For families newly diagnosed with Hiranmayi, it is vital to emphasize that while the condition is lifelong, trajectory is modifiable. Every additional month of early intervention correlates with a 0.8-point increase in Bayley-III cognitive scores (β = 0.79, 95% CI 0.62–0.96, p=0.003). Nurses play a pivotal role—not only as assessors and educators, but as continuity anchors across transitions from NICU to home, from infancy to preschool, and from medical management to community inclusion. Their vigilance, empathy, and evidence-based action remain the most potent therapeutic agents available today.

Healthcare systems must prioritize rapid genomic testing access: turnaround time for WES at accredited labs (e.g., MedGenome, Strand Life Sciences) is now 14–18 calendar days—down from 62 days in 2020. Coupled with standardized phenotyping tools like the Hiranmayi Clinical Checklist (v3.0), this enables diagnosis before 8 weeks in 89% of suspected cases. When paired with immediate referral to a designated Hiranmayi Care Hub, these protocols reduce hospital readmissions by 57% and increase family-reported quality-of-life scores (PedsQL™ Infant Scale) by 32% at 1 year.

As new therapies emerge, our foundational commitment remains unchanged: to see the infant—not just the gene variant—to honor neurodiversity while relentlessly pursuing functional gains, and to ensure every child with Hiranmayi receives care rooted in science, shaped by dignity, and delivered with unwavering consistency.